Post by Regeneron

Pushing the boundaries of what’s possible in science is at the core of what we do, and Q1 2026 reflected that commitment in meaningful ways for patients. Today we reported our first quarter financial and operating results, reflecting continued momentum across our pipeline, portfolio and broader work to expand patient access. Q1 2026 and Recent Highlights 🌟Received FDA approval for our first gene therapy, the first and only treatment for an ultra-rare form of genetic hearing loss in children, which we are proud to provide for free in the U.S.  ✍️ Reached an agreement with the U.S. government to help lower drug costs for American patients while preserving the innovation that drives new medicines  🌍 Secured new approvals and regulatory recommendations across dermatology, immunology and rare disease in the U.S., EU and Japan 🧬 Advanced our pipeline with a Priority Review acceptance for a potential first treatment for adults with an ultra-rare and progressively disabling bone disorder 🤝 Expanded our research efforts through strategic collaborations with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical therapies, and with TriNetX to access de-identified electronic health records of 300 million patients to accelerate research and product development 🎓 Renewed our sponsorship of the Regeneron Science Talent Search through 2036 with an additional $150M commitment, continuing our partnership with the Society for Science to support the nation's oldest and most prestigious science and math competition for high school seniors Thank you to our colleagues, collaborators, investigators and patients who make it all happen.  Read more: https://bit.ly/4ecsovE